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Background: Dual anti-human epidermal growth factor receptor 2 (HER2) therapies have been shown to improve
outcomes of HER2-positive breast cancer patients. We undertook a systematic review to compare treatment outcomes
for patients who received single or combined anti-HER2 therapies.
Methods: We identified randomized control trials that compared dual anti-HER2 therapy and anti-HER2 monotherapy
in patients with HER2-positive breast cancer. Outcomes included pathologic complete response (pCR), overall survival
(OS), progression-free survival (PFS), and adverse events. Included in the analysis were seven trials that recruited 2,609
patients.
Results: In the neoadjuvant setting, the pooled pCR rate in the dual anti-HER2 therapy and monotherapy groups in
combination with chemotherapy was 54.8% and 36%, respectively. This difference was statistically significant (relative
risk, 1.56; 95% confidence interval (CI), 1.23–1.97; p < 0.001). In the metastatic setting, dual anti-HER2 therapy
demonstrated significant benefits in both PFS (hazard ratio (HR), 0.71; 95% CI, 0.62–0.81; p < 0.001) and OS (HR, 0.68;
95% CI, 0.57–0.82; p < 0.001). Subgroup analyses indicated that the addition of chemotherapy to dual anti-HER2 therapy
could greatly improve pCR in the neoadjuvant settings. However, in the metastatic setting, similar PFS and OS were
found in patients receiving dual anti-HER2 therapy with or without chemotherapy. Dual anti-HER2 therapy was
associated with more frequent adverse events than monotherapy, but no statistical differences were observed in
cardiac toxicity.
Conclusions: This systematic review provides a summary of all the data currently available, and confirms the benefits
and risks of dual anti-HER2 therapy for HER2-positive breast cancer.
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Despite advances in early diagnosis and treatment, breast
cancer remains a significant public health concern; more
than a million new cases are diagnosed each year, resulting
in 400,000 deaths worldwide [1-3]. Human epidermal
growth factor receptor 2 (HER2) protein is overexpressed
in 15–20% of all breast cancers (HER2-positive breast can-
cer) and is associated with a poor outcome [4,5].
The development of trastuzumab, a monoclonal anti-
body against HER2, has dramatically changed the progno-
sis for HER2-positive breast cancer patients [6]. Multiple
randomized controlled trials (RCTs) have shown that tras-
tuzumab therapy improves patient outcomes, and conse-
quently trastuzumab has become the standard treatment
for HER2-positive breast cancer patients in both the neo-
adjuvant and metastatic settings [7,8]. Following trastuzu-
mab, lapatinib, an anti-HER2 tyrosine kinase inhibitor,
was approved for use, in combination with capecitabine,
for the treatment of HER2-positive metastatic breast can-
cer that has progressed with standard treatment [9,10].
Despite these improvements, resistance to these drugs
remains a challenge, and novel therapeutic approaches are
required [11,12]. The effect of combining different anti-
HER2-targeted agents is one therapeutic strategy currently
under investigation [13]. Laboratory studies have shown
that dual anti-HER2 therapy can block the signaling from
HER2 and its related HER family members more com-
pletely, leading to increased cell death and tumor shrink-
age in HER2-positive models of breast cancer [14]. The
addition of pertuzumab, an anti-HER2 monoclonal anti-
body, to trastuzumab and docetaxel therapy significantly
increases progression-free survival (PFS) for patients with
HER2-positive metastatic breast cancer (median PFS, 19.5
versus 12.4 months) [15]. These impressive results have
provided a strong rationale for conducting randomized
controlled studies evaluating trastuzumab in combination
with lapatinib or pertuzumab for HER2-positive breast
cancer in both the adjuvant and metastatic settings. In this
study, we conduct a systematic review of these RCTs to
summarize the benefits and risks of dual anti-HER2 ther-
apy, as compared with monotherapy, for HER2-positive
breast cancer patients.
Methods
Data sources, search strategy, and selection criteria
The systematic review was performed according to the
Quality of Reporting of Meta-analyses (QUORUM) guide-
lines [16]. We systematic searched PubMed, EmBase,
MEDLINE, and the Cochrane Central Registered Con-
trolled Trials for studies conducted prior to May 2013,
using the following keywords: trastuzumab, pertuzumab,
lapatinib, and breast cancer. The search was limited to
randomized clinical trials, but without language restric-
tions. In addition, the American Society of ClinicalOncology (ASCO) Annual Meeting proceedings and the
San Antonio Breast Cancer Symposium Meeting abstracts
from 2004 to 2013 were individually searched for relevant
randomized clinical trials. An independent search of rele-
vant reviews and meta-analyses regarding trastuzumab,
pertuzumab, or lapatinib was also conducted to ensure
that no studies were missed. We reviewed each publica-
tion, and only the most recent or complete report of clin-
ical trials was included when duplicate publications were
identified. Efforts were also made to contact the study au-
thors when relevant data were not clear.
The goal of this study was to evaluate the efficacy and
safety of dual anti-HER2 therapy compared to mono-
therapy. Thus, only RCTs comparing dual anti-HER2
therapy (lapatinib, trastuzumab, or pertuzumab) with
anti-HER2 monotherapy, with or without chemotherapy,
in breast cancer were eligible. Phase I trials and single-
arm phase II trials were excluded because of an absence
of controls. Eligible studies had to meet the following in-
clusion criteria: studies had to 1) be prospective phase II
and III trials with HER2 breast cancer patients, and 2)
assign patients randomly to anti-HER2 single agent or
combination treatment. The literature search and selec-
tion were undertaken independently by two investigators
(Xiao Zhang and Fei-Fei Yu), and any disagreement was
investigated by a third investigator (Xin-Ji Zhang) until a
consensus was reached.
Data extraction and quality assessment
Data extraction and collection was performed independ-
ently by two reviewers (Xiao Zhang and Fei-Fei Yu)
using a standardized protocol. Disagreements were adju-
dicated by a third reviewer (Xin-Ji Zhang) after referring
to the original articles. The following information was
extracted from each included study for baseline charac-
teristics: the first author’s surname, publication year, ori-
ginal country, age, number of patients per arm, dose and
duration of anti-HER2 therapy, type/dose of chemother-
apy, median follow-up period, and outcome measures.
End points of interest included overall survival (OS),
PFS, pathologic complete response (pCR), and adverse
events (AEs). The quality of the trials included in this
study were assessed using the Jadad scale [17]. The trials
were assessed on the basis of randomization, conceal-
ment of treatment allocation, blinding, completeness of
follow-up, and the use of intention-to-treat analysis.
Statistical analysis
We extracted the adjusted hazard ratio (HR) and corre-
sponding 95% confidence interval (CI) from each RCT to
estimate the pooled HR, and corresponding 95% CI, for
OS and PFS in the dual anti-HER2 therapy and monother-
apy groups. We also allocated dichotomous frequency
data to assess the pooled relative risks (RRs), and
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anti-HER2 therapy and monotherapy groups. Included in
the analysis were five three-arm trials, with two anti-
HER2 monotherapy arms and one dual anti-HER2 therapy
study. The two anti-HER2 monotherapy arms were
merged into one group by adding the sample size and the
number of events in each arm. Subgroup analyses were
performed according to the addition of chemotherapy and
the component drugs of dual anti-HER2 therapy (trastu-
zumab + lapatinib or trastuzumab + pertuzumab). When
there was no statistically significant heterogeneity, a
pooled effect was calculated using a fixed-effect model;
otherwise, a random-effect model was employed. Hetero-
geneity of treatment effects between trials was evaluated
using the chi-square (χ2) test and I-squared (I2) statistic
[18]. We also assessed the probability of publication bias
using the Egger’s [19] and Begg–Mazumdar [20] tests.
Statistical analyses were carried out using STATA 11.0
(State Corporation, Lake Way, Texas, USA). A two-tailed
p value <0.05 was considered statistically significant.
Results
Search results and trial characteristics
We identified 737 potentially relevant trials from our ini-
tial electronic search, and excluded 685 trials after a pre-
liminary review. The remaining 52 studies were retrieved
for detailed assessment. Of these, 44 articles were ex-
cluded because they contained no combination therapyFigure 1 Flow diagram of the trial search and selection process.group, were phase II trials without a control arm, or they
were not phase II or phase III studies. An additional art-
icle was included by searching ASCO 2012 Annual Meet-
ing abstracts [21]. A further two studies were excluded
because they were duplicates [22,23]; only the most recent
reports were included [15,24]. Therefore, a total of seven
[15,21,24-28] RCTs were included in our final analysis,
which included data on 2,609 individual patients (Figure 1).
The design characteristics of the included trials are pre-
sented in Table 1. The role of dual anti-HER2 therapy in
the neoadjuvant setting was evaluated in five trials
[21,25-28] and two trials [15,24] investigated dual anti-
HER2 therapy in the metastatic setting. All the breast can-
cer patients were HER2-positive. The quality of the trials
was assessed according to the pre-determined criteria of
the Jadad score. Overall, three trials had a Jadad score of 5
[23,26,27], three trials had a score of 4 [21,25,28], and one
trial had a score of 3 [24].
pCR in neoadjuvant studies
pCR was evaluated in a total of five trials [21,25-28], all
which investigated the effect of anti-HER2 therapy in the
neoadjuvant settings. In these trials, anti-HER2 agents
were combined with chemotherapy: paclitaxel in three tri-
als [21,26,27], FEC in one trial [28], and docetaxel in the
remaining one trial [25]. There was also one arm without
chemotherapy in the Neo-Sphere trial [25], and this arm
was excluded in the pooled analysis. The pooled pCR rate













2 Neoadjuvant T 36 2 mg/kg weekly (loading 4 mg/kg) Paclitaxel 26 weeks 50 5 NA
L 39 1500 mg daily Paclitaxel 26 weeks 49 NA
L + T 46 1000 mg daily + 2 mg/kg weekly (loading 4 mg/kg) Paclitaxel 26 weeks 49 NA
NeoALTTO27
(2012)
3 Neoadjuvant L 149 1500 mg daily Paclitaxel 18 weeks 50 5 NA
T 154 2 mg/kg weekly (loading 4 mg/kg) Paclitaxel 18 weeks 49 NA
L + T 152 1000 mg daily + 2 mg/kg weekly (loading 4 mg/kg) Paclitaxel 18 weeks 50 NA
NSABP B-4121
(2012)
3 Neoadjuvant T 177 2 mg/kg weekly (loading 4 mg/kg) Paclitaxel 12 weeks NA 4 NA
L 171 1250 mg daily Paclitaxel 13 weeks NA NA
L + T 171 750 mg daily + 2 mg/kg weekly (loading 4 mg/kg) Paclitaxel 14 weeks NA NA
NeoSphere25
(2012)
2 Neoadjuvant T 107 6 mg/kg q3w (loading 8 mg/kg) Docetaxel 12 weeks 50 4 NA
T + P 107 6 mg/kg q3w (loading 8 mg/kg) + 420 mg/kg q3w
(loading 840 mg/kg)
docetaxel 13 weeks 50 NA
T + P 107 6 mg/kg q3w (loading 8 mg/kg) +420 mg/kg q3w
(loading 840 mg/kg)
NO 14 weeks 49 NA
P 96 420 mg/kg q3w (loading 840 mg/kg) docetaxel 15 weeks 49 4 NA
Holmes28
(2012)
NA Neoadjuvant T 33 2 mg/kg weekly (loading 4 mg/kg) FEC 26 weeks NA NA
L 34 1250 mg daily FEC 27 weeks NA NA
L + T 33 750 mg daily + 2 mg/kg weekly FEC 28 weeks NA NA
EGF10490024
(2012)
3 Metastatic L + T 148 1000 mg daily + 2 mg/kg weekly No Until progression or
unacceptable toxicity
51 3 12.8





3 Metastatic P + T 402 6 mg/kg q3w (loading 8 mg/kg) + 420 mg/kg q3w
(loading 840 mg/kg)
Docetaxel Until progression or
unacceptable toxicity
54 5 30
Placebo + T 406 6 mg/kg q3w (loading 8 mg/kg) Docetaxel Until progression or
unacceptable toxicity
54 30
Abbreviations: T Trastuzumab, L Lapatinib, P Pertuzumab, pts no patients number, mg milligram, kg kilogram, Pacl Paclitaxel, FEC Fluorouracil (5FU), epirubicin, and cyclophosphamide; q3w three-weekly,
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http://www.biomedcentral.com/1471-2407/14/625was 54.8% (278 of 508 patients; 95% CI, 0.46–0.63) in the
dual therapy group compared with 35.6% (442 of 995 pa-
tients; 95% CI, 0.24–0.50) in the monotherapy group. The
difference in pCR between dual agents and single anti-
HER2 agents was significant (RR, 1.56; 95% CI, 1.23–1.97;
p < 0.001), with no evidence of significant publication bias
(Egger’s test, P = 0.624; Begg-Mazumdar test, P = 0.9370;
Figure 2).We noted some evidence of heterogeneity in the
magnitude of this effect across the included studies (p =
0.006, I2 = 72.3%), which was mostly attributable to inclu-
sion of the NSABP B-41 study [21]. A sensitivity analysis
that excluded the NSABP B-41 study resulted in a similar
RR (1.74; 95% CI, 1.49–2.03; p < 0.001) with much reduced
heterogeneity (p = 0.67, I2 = 0.00%).
PFS and OS in metastatic studies or setting
In our analysis, two studies [15,24] investigated the effect
of dual anti-HER2 therapy in the metastatic setting. The
CLEOPATRA study was a phase III study that included
808 patients with HER2-positive metastatic breast cancer
[15]. In this study, patients were randomized to first-line
treatment of pertuzumab + trastuzumab + docetaxel (dual
anti-HER2 therapy group) or trastuzumab + docetaxel +
placebo (control group). The median PFS was 18.7 months
in the dual anti-HER2 therapy group and 12.4 months in
the control group. The difference in PFS was significant
(HR, 0.69; 95% CI, 0.58–0.81; P < 0.001). Furthermore, a
significant benefit in OS was also observed in patients al-
located to the dual anti-HER2 therapy treatment group
compared with individuals assigned to the control group
(HR, 0.66; 95% CI 0.52 − 0.84; p < 0.001). The median OS
for patients allocated to the control group was 37.6 months
but was not reached in the dual anti-HER2 therapy group.
Another phase III study (EGF104900) enrolled patients
with HER2-positive metastatic breast cancer whose dis-
ease had progressed during prior trastuzumab therapyRisk ratio










Figure 2 Meta-analysis of pathologic complete response between du[24]. In this study, 296 patients were randomly assigned to
receive either lapatinib + trastuzumab (dual anti-HER2
therapy group) or lapatinib monotherapy (control group).
The median PFS was 11.1 and 8.1 weeks in the dual anti-
HER2 therapy and control groups, respectively. Median
OS was 14 months for the dual anti-HER2 therapy group
and 9.5 months for the lapatinib alone group. The dual
anti-HER2 therapy group showed significant improve-
ments in PFS (HR, 0.74; 95% CI, 0.58–0.94; P = 0.011) and
OS (HR, 0.74; 95% CI, 0.57–0.97; P = 0.026). Although
these two trials had different patient populations and set-
tings, both showed a significant improvement in OS and
PFS with dual anti-HER2 therapy.Subgroup analysis
Subgroup analyses were performed to determine whether
the type of neoadjuvant chemotherapy influenced the effi-
cacy of dual anti-HER2 therapy. We found that the benefit
of dual anti-HER2 therapy on pCR was similar among dif-
ferent chemotherapies. Detailed information regarding
these analyses is summarized in Table 2.
We also performed subgroup analyses based on the
component drugs of dual anti-HER2 therapy (trastuzu-
mab + lapatinib or trastuzumab + pertuzumab). The re-
sults of this subgroup analysis indicated that there were
improvements in pCR in dual anti-HER2 therapies con-
sisting of trastuzumab + lapatinib (RR, 1.52; 95% CI, 1.15–
2.01) and trastuzumab + pertuzumab (RR, 1.72; 95% CI,
1.27–2.34; Table 2). Compared with monotherapy, dual
anti-HER2 therapy consisting of trastuzumab + lapatinib
showed a decrease in the HR for disease progression and
death of 26% and 29%, respectively. Similar benefits in
PFS (HR, 0.69; 95% CI, 0.58–0.81) and OS (HR, 0.66; 95%
CI, 0.52–0.84) were also observed with trastuzumab + per-
tuzumab dual anti-HER2 therapy.50
RR  ( 95%  CI )Weight( % )
1.82 ( 1.10, 2.99) 12.6 
1.90 ( 1.49, 2.41) 22.5 
1.72 ( 1.27, 2.34) 19.6 
1.17 ( 1.01, 1.37) 26.2 
1.48 ( 1.07, 2.03) 19.0 
1.56 ( 1.23, 1.97) 100.0 
al anti-HER2 therapy and monotherapy groups.
Table 2 Subgroup analysis based on the type of
chemotherapy and the component of dual agents
Subgroup Reference pCR
The type of Chemotherapy 21,25,26,27,28 1.56 (1.23,1.97)
Paclitaxel 21,26,27 1.55 (1.06,2.28)
FEC 28 1.48 (1.07,2.03)
Docetaxel 25 1.72 (1.27,2.34)
Component of dual agents
L + T 21,26,27,28 1.52 (1.15,2.01)
P + T 25 1.72 (1.27,2.34)
Abbreviations: T Trastuzumab, L Lapatinib, P Pertuzumab.
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The use of dual anti-HER2 therapy was associated with
an increase in serious AEs (RR, 1.22; 95% CI, 1.03–1.46;
p = 0.024). In addition, dual anti-HER2 therapy increased
the risk of grade 3–4 diarrhea (RR, 1.64; 95% CI, 1.26–
2.13; p < 0.001), all grades of dermatologic toxicity (RR,
1.41; 95% CI, 1.19–1.68; p < 0.001), and febrile neutro-
penia (RR, 1.55; 95% CI, 1.08–2.23; p = 0.143). No statis-
tically significant differences were observed between the
two arms for neutropenia (RR, 0.99; 95% CI, 0.88–1.10;
p = 0.645), hepatic toxicity (RR, 1.01; 95% CI, 0.66–1.55;
p = 0.818), grade 3-4 dermatologic toxicity (RR, 1.28;
95% CI, 0.73–2.23; p = 0.378), nausea (RR, 1.04; 95% CI,
0.90–1.20; p = 0.597), or fatigue (RR, 1.01; 95% CI, 0.86–
















Figure 3 Meta-analysis of adverse events between dual anti-HER2 theCardiac toxicity
The risk of heart failure was reported in six trials
[15,21,24-27]. Overall, there was no statistically signifi-
cant difference in the risk of heart failure between dual
anti-HER2 therapy and monotherapy (RR, 0.79; 95% CI,
0.23–2.68; p = 0.708). There were five trials [15,24-27]
that reported data for left ventricular ejection fraction
(LVEF) decline, but no statistically significant difference
in risk between the treatment groups was found (RR,
1.12; 95% CI, 0.51–2.44; p = 0.773; Figure 4).
Discussion
This systematic review summarizes all the available pub-
lished, randomized evidence on the efficacy and safety of
dual anti-HER2 therapy compared with monotherapy in
HER2-positve breast cancer patients. Preclinical studies
have suggested that combining different HER2 inhibitors
with complementary mechanisms of action can help
maximize the suppression of oncogenic processes involved
in disease progression. Consequently, an increasing num-
ber of clinical trials have been performed to investigate
this promising therapeutic approach [15,24,25]. Combin-
ing data from all the currently published trials, this
systematic review confirms the benefit of dual HER2-
directed therapy over monotherapy for HER2-positve
breast cancer.
By pooling the data from the included trials, we showed






































































rapy and monotherapy groups.
Risk ratio
.02 .2 1 5 50
NSABP B−41 0.14 ( 0.02, 1.09) 6.3 
CLEOPATRA 0.63 ( 0.37, 1.05) 30.0 
EGF104900 2.96 ( 0.31, 28.13) 5.2 
NeoALTTO 5.96 ( 0.24, 145.46) 2.8 
CHER−LOB (Excluded)
NeoSphere (Excluded)
0.79 ( 0.23, 2.68) 44.2 
EGF104900 2.61 ( 0.71, 9.66) 12.3 
CHER−LOB 0.54 ( 0.02, 12.96) 2.8 
CLEOPATRA study 0.62 ( 0.35, 1.11) 28.2 
NeoALTTO 1.00 ( 0.09, 10.91) 4.7 
NeoSphere 2.82 ( 0.48, 16.60) 7.8 
1.12 ( 0.51, 2.44) 55.8 





(     =5.77,   =48.0%, p=0.123）Heterogeneity 2χ I2
(     =5.80,   =31.0%, p=0.215）Heterogeneity
2χ I2
Figure 4 Meta-analysis of cardiac toxicity between dual anti-HER2 therapy and monotherapy groups.
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http://www.biomedcentral.com/1471-2407/14/625rate in the neoadjuvant setting (RR, 1.56; 95% CI, 1.23–
1.97; p < 0.001). Hence, dual anti-HER2 therapy might be
an attractive strategy in this setting. In the metastatic set-
ting, dual anti-HER2 therapy, compared to monotherapy,
demonstrated significant benefits for OS and PFS in the
EGF104900 and CLEOPATRA studies. However, because
of the limited data regarding metastatic disease, these ben-
efits require further study.
Despite the advantages of dual anti-HER2 therapy in
the neoadjuvant settings, a number of questions have
arisen: 1) does the type of chemotherapy alter the effi-
cacy of dual anti-HER2 therapy; and 2) which combin-
ation of the HER2 inhibitors has optimal efficacy for
HER2-positive breast cancer. In this study, subgroup
analyses were conducted to address these questions.
When grouped by the type of chemotherapy, the im-
provement in the pCR rate with dual anti-HER2 therapy
was similar, regardless of the specific chemotherapies
used. Furthermore, similar efficacy was observed with
trastuzumab + pertuzumab and trastuzumab + lapatinib.
Based on current data, it appears that the type of
chemotherapy and specific components of dual anti-
HER2 therapy have little impact on the efficacy of the
treatment. However, due to the limited number of trials
in each subgroup, these results need to be validated in
further studies.
Our study also raises some safety concerns. As the
HER2 signaling pathway plays an important role in car-
diac physiology [29], we investigated the risk of cardiac
AEs. We found that no increased risk of cardiac toxicity
was associated with dual anti-HER2 therapy, which is
consistent with the results of a previous study con-
ducted by Valachis et al. [30]. However, we found thatsome other toxicities were more frequent in patients
who received dual anti-HER2 therapy, particularly grade
3–4 diarrhea, dermatologic toxicity, mucosis, febrile
neutropenia, and other serious AEs. Clinicians should
take note of this, since the incidence of AEs substan-
tially affects a patient’s quality of life, and may lead to
discontinuation of dual treatment.
Several limitations of this systematic review should be
acknowledged. Firstly, data from the ongoing ALTTO
and MARIANNE [14] trials are still unavailable. Sec-
ondly, our results are based on published data and pre-
sented clinical trials; individual patient data were not
unavailable. Thirdly, because the results of this meta-
analysis are confined to trastuzumab + lapatinib or tras-
tuzumab + pertuzumab, the results are not necessarily
applicable to treatments using other drug combinations. In
addition, some subgroup analyses were based on limited
studies, and the results should be interpreted with caution.
Conclusions
This systematic review shows that, according to the present
available data, dual anti-HER2 therapy seems to be more ef-
fective than monotherapy in the neoadjuvant setting. In the
metastatic setting, limited data is available and further
evaluation of the role of dual anti-HER2 treatment is re-
quired. However, it is reasonable to believe that a shift
towards a dual therapeutic approach will yield clinically
meaningful improvements for patients with HER2-postive
breast cancer. However, given the increased risk of AEs
associated with dual anti-HER2 therapy, it is important for
health care practitioners to be aware of the potential risks
and to provide close monitoring to improve patient
outcome.
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